PDTM-36. WHOLE EXOME SEQUENCING (WES) OF DIPG PATIENTS FROM THE BIOMEDE TRIAL REVEALS NEW PROGNOSTIC SUBGROUPS WITH SPECIFIC ONCOGENIC PROGRAMMES

BACKGROUND & METHODS. The BIOlogical MEdicines for DIPG Eradication (BIOMEDE) trial is a randomized multi-arm multi-stage program (drop-the-loser adaptive design). The first trial was an open-label phase-II trial comparing three drugs (everolimus, dasatinib, erlotinib) combined with irradiation,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Debily, Marie-Anne, Kergrohen, Thomas, Varlet, Pascale, Le Teuff, Gwenael, Nysom, Karsten, Blomgren, Klas, Leblond, Pierre, Bertozzi, Anne-Isabelle, De Carli, Emilie, Chappé, Celine, Ghermaoui, Samia, Barret, Emilie, Picot, Stephanie, Tauziède-Espariat, Arnaud, Puget, Stephanie, Castel, David, Vassal, Gilles, Grill, Jacques
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Pediatric Tumors
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846998/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.812
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados